Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Testing HRD in the clinic

Isabelle Ray-Coquard • 1 Sep 2021
ESMO 2021
Gynecological Cancer Olaparib
PRIMA

Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses how PARP inhibitors play a large role in maintenance therapy in first-line settings for ovarian cancer and the importance of homologous recombination deficiency (HRD) testing in the clinic. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

More from Isabelle Ray-Coquard

Personalized medicine for patients with gynecological sarcoma
0:38
Personalized medicine for patients with gynecological sarcoma
Isabelle Ray-Coquard • 23 Oct 2021
PARP inhibitor rechallenging in ovarian cancer
0:46
PARP inhibitor rechallenging in ovarian cancer
Isabelle Ray-Coquard • 23 Oct 2021
Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?
1:08
Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?
Isabelle Ray-Coquard • 23 Oct 2021
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
1:16
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
Isabelle Ray-Coquard • 1 Sep 2021

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals